AlphAIAlphAI — Financial news for AI agents
prnewswire.comOCT 52 min read$ABBV

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

AbbVie (ABBV) and Genmab (GMAB) reported positive Phase 3 trial results for epcoritamab combined with R-CHOP in diffuse large B-cell lymphoma (DLBCL). The trial showed a 51% reduction in disease progression or death risk. Both companies plan to engage regulators based on these findings.

Original reporting
prnewswire.com
Published Oct 5, 2026, 6:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 6:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV · $GMAB
Relevance
9/10
AlphAI data visualization · based on prnewswire.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The data represent a pivotal efficacy signal that could lead to regulatory submissions and commercial rollout, impacting both AbbVie and Genmab valuations.

02

Market read

First report of significant Phase 3 results for a lymphoma therapy; likely to move both stocks and influence the broader oncology biotech space.

03

What to watch

Potential competition from other bispecifics and the need for FDA filing strategy.

Relevance 9/10Novelty 9/10Timing: today

Background

The article is a PR release announcing first interim analysis of a Phase 3 trial for epcoritamab combined with R-CHOP in newly diagnosed DLBCL patients.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie announced positive Phase 3 EPCORE DLBCL-2 trial results showing a 51% reduction in risk of progression versus R-CHOP alone.

Expected impact

upward pressure as investors price in potential revenue from epcoritamab in frontline DLBCL.

Evidence & confidence

First disclosure of statistically significant PFS improvement; large oncology franchise and U.S. listing make the news material.

$GMABBullishHigh confidence
Context

Genmab reported the same Phase 3 EPCORE DLBCL-2 topline results, confirming a 51% risk reduction in progression.

Expected impact

upward pressure as market anticipates licensing revenue and potential FDA filing.

Evidence & confidence

First report of pivotal trial success for a product co-developed with AbbVie; significant for Genmab's pipeline.

Market effects

Sector

Strengthens the oncology/biotech sector outlook, especially for bispecific antibodies.

Regional

Positive for U.S. and European biotech markets where both companies are listed.

Global

Adds confidence to global lymphoma treatment pipelines, may influence peer valuations.

Counterpoint

What could challenge this read

If regulatory scrutiny delays approval, the initial hype could fade and cause a pullback.

Key entities

  • Company
    AbbVie

    U.S.-based biopharma partner developing epcoritamab.

  • Company
    Genmab A/S

    Danish biotech co-developer of epcoritamab.

Read at source← All news

Also covered by

4 outlets

Related articles

OCT 6
$ABBVMed

AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%

AbbVie (ABBV) shares rose 0.3% to $266.63 on Oct. 6 after a late-stage trial showed its blood-cancer treatment, epcoritamab plus R-CHOP, reduced the risk of disease progression or death by 51% compared to R-CHOP alone in diffuse large B-cell lymphoma. The trial's hazard ratio was 0.49, with a p-value below 0.0001, and safety was consistent with known profiles.

finance.yahoo.com2 min
OCT 6
$ABBVHighAI 9/10

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

AbbVie (ABBV) and Genmab (GMAB) reported positive phase III trial results for epcoritamab combined with R-CHOP in frontline DLBCL, showing a 51% reduction in disease progression or death. The study met its primary endpoint, and the combo was well-tolerated. Both companies plan regulatory discussions. AbbVie's shares are up 19.1% YTD. Epcoritamab is approved as a monotherapy in several regions.

theglobeandmail.com2 min
OCT 6
$ABBVHighAI 9/10

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

Genmab and AbbVie's Epkinly, combined with chemotherapy, reduced disease progression or death risk by 51% in a Phase 3 lymphoma trial. The results exceeded expectations and could boost Epkinly's sales. Genmab reported $312M in Epkinly sales in H1 2024, and its shares rose 14% on the news. Epkinly may become the first drug of its kind approved for first-line DLBCL.

finance.yahoo.com2 min
OCT 6
$ABBVMed

AbbVie and Genmab Report 51% Reduction in Progression With Epcoritamab Plus R-CHOP in Diffuse Large B-cell Lymphoma

AbbVie and Genmab reported Phase 3 trial results showing a 51% reduction in disease progression or death for epcoritamab plus R-CHOP in diffuse large B-cell lymphoma (DLBCL) patients with IPI scores of 2-5. The combination therapy met its primary endpoint, improving progression-free survival. The companies plan to discuss the findings with regulators. Epcoritamab is an investigational bispecific antibody.

oncodaily.com2 min